Socio-economic determinants of disease progression among HIV infected adults in Kenya by unknown
RESEARCH ARTICLE Open Access
Socio-economic determinants of disease
progression among HIV infected adults in Kenya
Nyawira T. Gitahi–Kamau1*, James N. Kiarie1, Kenneth K. Mutai4, Beatrice W. Gatumia5, P. M. Gatongi2 and A. Lakati3
Abstract
Background: Socioeconomic determinants have been shown to have an effect on the progression of HIV disease
evidenced by studies carried out largely in developed countries. Knowledge of these factors could inform on
prioritization of populations during scale up of highly active antiretroviral therapy (HAART) constrained health
systems. The objective of this study was to identify socioeconomic correlates of HIV disease progression in an adult
Kenyan population.
Methods: We analysed data from 312 HIV positive individuals, drawn from a cohort enrolled in a randomized
clinical trial investigating the effectiveness of Acyclovir in the prevention of HIV transmission among serodiscordant
couples. In this study we included individuals with CD4 counts ≥ 350 cells/mm3 and World Health Organization
(WHO), clinical stage one or two. The exposure variables measured were: - daily household income available for
expenditure, age, gender, housing type and level of formal education. We used a composite outcome of disease
progression to WHO clinical stage 3 or 4 or a laboratory outcome of CD4 count below 350 cells/mm3 after two
years of follow-up. Logistic regression was used to determine associations of variables that were found to be
significant at univariate analysis, and to control for potential confounders.
Results: Seventy eight (25 %) individuals reported HIV disease progression. Majority (79.9 %) were female. The
median age was 30 year and 93.6 % had attained a primary level of education. Median CD4 at enrolment into the
clinical trial was 564 cells/mm3; those who had disease progression were enrolled with a significantly (p < 0.001)
lower CD4 count. Daily household income available for expenditure adjusted for CD4 count at enrolment was
associated significantly (p = 0.04) with HIV disease progression. Disease progression was five times more likely to
occur in study subjects with daily income available for expenditure of less than US$1 compared to those with more
than US$ 5 available for daily expenditure [adjusted Odds Ratio 4.6 (95 % Confidence Interval 1.4–14.4)]. Disease
progression was not associated with age, gender, type of housing or level of education attained (p < 0.05).
Conclusion: Populations with low household incomes should be considered vulnerable to disease progression and
should therefore be prioritized during the scale up of HAART for treatment as prevention.
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Background
HIV disease progression to Acquired Immune Deficiency
Syndrome (AIDS) is one of the greatest contributors of
mortality in Africa [1]. A large number of infections occur
among serodiscordant couples [2]. The progressive loss of
CD4+ T lymphocytes during HIV infection eventually
results in an inability to mount an adequate immune re-
sponse to opportunistic pathogens resulting in death [3].
Socioeconomic determinants such as age, sex, and in-
come are reported as contributors to disease progression
[4–8] in HIV infected individuals who are not on highly
active antiretroviral therapy (HAART). These factors
may still continue to influence the uptake of care and
treatment even, where these services are provided at no
cost to the individual. There is a paucity of data on the
effects of socioeconomic determinants of disease pro-
gression among HIV infected individuals in sub-Saharan
Africa.
The World Health Organization (WHO) recommends
the treatment of all HIV positive individuals in a discordant
relationship regardless of their CD4 count and all adults
and adolescents with CD4 cell counts below 500 cells/mm3
[9] should receive treatment. The implementation of these
guidelines [9] in low-income countries like Kenya [10] may
be hindered due to the financial considerations on already
strained health systems. To alleviate this, low and middle-
income countries commonly use a phasic approach in the
implementation of HAART scaling up [11]. Integration of
clinical and sociodemographic criteria would be useful in
the in prioritization of vulnerable populations. The object-
ive of this study was to identify socioeconomic correlates of
disease progression in HIV infected adults in serodiscor-
dant relationships.
Methods
This study was conducted in a sample of HIV positive in-
dividuals drawn from a randomized clinical trial (RCT)
carried out in a serodiscordant couple’s clinic in Nairobi.
The RCT was investigating Acyclovir in the prevention of
HIV transmission (HSV2/HIV1 study) - clinical trials no:
NCT00194519 [12]. We analysed data from 312 HIV posi-
tive individuals drawn from a cohort of 416 study partici-
pants for a period of two years beginning in November
2011 and ending in June 2013. Participants were selected
from the main cohort based on CD4 count of above 350
cells/mm3 and WHO clinical stage 1 or 2 at enrolment
into the clinical trial. We excluded HIV positive individ-
uals who seroconverted during the clinical trial [10]. Out
of the total cohort initially enrolled in the clinical trial, 86
were excluded due to CD4 counts of ≤350 cells/mm3 at
enrollment, because they were eligible for HAART accord-
ing to the Kenya national guidelines 2011 [13]. End point
outcomes for 18 participants (5 %) were unavailable
because they were reported as lost to follow up (n = 11) or
dead (n = 7) during the clinical trial. A summary of the
cohort is illustrated in Fig. 1.
Disease progression was defined as a composite outcome
of WHO clinical staging criteria stages 3 and 4 or CD4
count of < 350 cells/mm3. Outcomes were evaluated at six
month intervals over the two years. Socio-demographic and
economic predictors of disease investigated included daily
income available for expenditure, level of education, hous-
ing settlement, age, and sex.
Data analysis
Statistical analysis was performed using SPSS version 17.0.
The main outcome was HIV disease progression which
was a composite outcome of CD4 less than 350 cells/mm3
and/or WHO clinical stage 3 or 4 within the 2-year follow
up period. Available daily income for expenditure was cat-
egorized as < US$1, US$1–5 and >US$5 .We took into ac-
count taking the World Bank (WB) definitions of extreme
poverty and poverty as having daily income available for
expenditure below US$1.25 and below $2 respectively. We
also allowed for the variations that occur within countries
[14]. Chi-square tests were used to determine differences
in disease progression (by both WHO staging and CD4
count criteria) across demographic, socioeconomic, and
clinical characteristics. Mann Whitney U test was used to
compare median CD4 at enrolment between the two dis-
ease progression groups. Logistic regression was carried
out to determine independent predictors of HIV disease
progression. CD4 count at enrolment (baseline) was a
known confounder of disease progression and was in-
cluded in the regression model after normalization
through cube root transformation. All statistical tests were
significant at a p value ≤0.05.
Ethical considerations
The HSV2/HIV1 study involved rigorous informed con-
sent and counselling sessions during the enrolment of par-
ticipants. Ethical approval was obtained from the Kenyatta
National Hospital ethics research committee and the insti-
tutional regulatory board of University of Washington.
The approvals allowed for the use of archived data and
stored samples for future studies. The current study was




The 312 individuals analyzed, entered the study in early
HIV disease; characterized as WHO stage 1 or 2, or a
CD4 count ≥350 cells/mm3. Eighty percent of all the
study participants were female. Median age was 30 years
(Interquartile Range [IQR]; 26, 35) with majority (91 %),
below 40 years. The median household daily income for
expenditure was $3 (IQR 1.25, 7). The population was
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highly literate with only 6.4 % reporting no basic education.
Majority (61.2 %) of the participants lived in formal housing
settlements. A summary of the background characteristics
is shown in Table 1.
Disease progression
HIV disease progression occurred in 25 % (95 % CI
20.5–30.1 %) of the participants; 20.5 % showed progres-
sion based on CD4 count criteria (<350 cells/mm3) and
4.5 % depicted progression by WHO clinical staging cri-
teria alone. During the two year follow up there were four
reported deaths; three of which were from HIV associated
conditions and one with no definitive diagnosis. Median
CD4 count at baseline was 566 cells/ml (IQR 444, 566).
There was a significant (p = 0.03) difference in median
CD4 count for those who had progressed toCD4 counts
of <350 cells/mm3 and those who had not. This difference
indicated that CD4 count at entry was a confounder to be
included in the logistic regression model during multivari-
ate analyses. Daily income available for expenditure was
found to be significantly (p = 0.04) associated with disease
progression. There was no significant (p ≤ 0.05) associ-
ation found at bivariate analyses of age, gender, level of
education, housing and disease progression by CD4 count
decline. As illustrated in Table 2.
Correlates of disease progression
At multivariate analysis, slower disease progression was as-
sociated significantly (p = 0.01) with reported available daily
income for expenditure of more than US$5; [adjusted Odds
Ratio (aOR) 4.6 (95 % Confidence Interval (CI) 1.4–14.4] as
compared to incomes of < $1. However this association was
not significant (p = 0.057) at available daily incomes of
between $1–5. CD4 count levels at enrolment remained a
significant (p < 0.001) predictor of disease progression (aOR
0.3 [95 % CI 0.2–0.4]. All the other variables in the model
which included age, sex and clinical trial intervention were
not independently associated with disease progression.
Similarly, a significantly smaller proportion (19.4 %) of the
participants who had received acyclovir as the clinical trial
intervention had progressed compared to those in the
placebo group (31.7 %), p = 0.013. As illustrated in Table 3.
Discussion
In this study there were more HIV- infected individuals,
who showed progression based on WHO clinical staging
criteria compared to those showing progression based
on CD4 count criteria. This is similar to studies in the
PRE-HAART era [15] where disease progression was re-
ported earlier when defined by laboratory criteria rather
than by the development of an opportunistic infection.
This study found a strong association between daily in-
comes and disease progression portrayed by a decrease in
CD4 counts to below 350 cells/mm3 (p = 0.026 CI 95 %).
This progression occurred in spite of the optimal provision
of free HIV care and treatment for opportunistic infections
and prophylaxis using cotrimoxazole or dapsone. Income
as a determinant of disease progression was strengthened
by finding of an association between higher daily income
available for expenditure and delayed disease progression.
The acyclovir arm had been reported as having displayed
delayed disease progression in the larger study [12]. Stud-
ies in America and Canada [5, 6] have reported a similar
association between low incomes and more rapid HIV dis-
ease progression. Additional evidence shows, higher rates
of disease progression after seroconversion among indi-
viduals with low incomes levels prior to infection [9]. The
association between income and disease progression can
Fig. 1 Cohort selection
Gitahi–Kamau et al. BMC Public Health  (2015) 15:733 Page 3 of 6
therefore not be explained by a reduction of income due
to HIV infection and morbidity. We postulate that micro-
nutrient deficiencies which are common in low-income
countries and have been proven to compromise the im-
mune systems of HIV infected individuals [16] may play a
role in the rate of disease progression observed [16]. Even
with most treatment programmes providing multivitamin
supplementation to individuals in care and treatment,
People Living with HIV (PLWHIV) still bear a heavy bur-
den of dietary micronutrient supplementation which is af-
fected by the daily income available for expenditure. This
contributes to the [16] weakening of the immune system
and the depletion of CD4 cells resulting in faster disease
progression. Micronutrient deficiency in the diet may
explain the strong association found in this study between
income available for daily expenditure and disease progres-
sion. Even with HAART provision, low income levels con-
tinue to be associated with poor health outcomes. In Kenya
the inability to pay for transport to a HAART provision
centre results in poor uptake of HAART [17]. Similarly, a
study in British Columbia also reported the inability to pay
for transport to a treatment centre as a cause of poor treat-
ment outcomes among individuals with low-income [18].
The cost of transport to a treatment centre may therefore
be another reason for the association between HIV disease
progression and daily income available for expenditure.
Studies in Tanzania, Uganda and France [5, 19, 20] have
found higher rates of disease progression in individuals
above 40 years. This study did not find an association
(p = 0.68; p < 0.05) between age, and disease progres-
sion. The finding of age as a non-determinant of dis-
ease progression in this study was most likely due to
only 9 % of the participants’ being above 40 years. This
study also found no association (p = 0.06; p < 0.05) be-
tween sex and disease progression measured using WHO
criteria or a reduction in CD4 counts. This finding was
corroborated by findings of various studies [6, 7] including
a meta-analysis of 23 cohorts from Europe, Australia, and
Canada which reported no association between sex and
HIV disease progression [7]. The lack of association be-
tween level of education and disease progression in this
study corresponds to findings in other similar studies of
HAART naive individuals [5, 8]. Associations have been
found in individuals already on HAART [21] with in-
creased level of education. This delayed progression is at-
tributed to the empowered attitude towards treatment
and care resulting from higher levels of education. This
did not apply to this study which focused on the period
before initiation of HAART.
This study is unusual as it integrated widely accepted
definitions of poverty [14] during analysis allowing
comparison of results among other low and middle in-
come countries within a global context. The study was
conducted in a cohort of HIV positive individuals in
serodiscordant unions who were all participating in a
controlled trial. This may have introduced some level
of selection bias though it is important to note that
progression of disease is not expected to be different
from other HIV positive individuals. The retrospective
study design limited the socioeconomic indicators
available to those captured during data collection for
HSV2/HIV1 study clinical trial as this study was retro-
spective [12].
The data presented here however indicates that poverty,
defined as the level of daily income available for expend-
iture, influences pre-HAART HIV disease progression and
deserves consideration as a contextual factor in HIV dis-
ease progression. Additionally, impoverished populations
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Table 2 Demographic and socio-economic characteristics associated with HIV disease progression
Independent variable Disease progression after two years n (%) No Disease progression after two years n (%) p value
Sex
Male 21 (34.4) 40 (65.6) 0.058
Female 57 (22.7) 194 (77.3)
Age
24 years 12 (22.2) 42 (77.8) 0.685
25-34years 42 (24.0) 133 (76.0)
35-44years 20 (30.8) 45 (69.2)
>45 years 4 (22.2) 14 (77.8)
Level of education
None 4 (20) 16 (80) 0.754
Primary 30 (23.4) 98 (76.6)
Secondary 28 (25.2) 83 (74.8)
Tertiary 16 (30.2) 37 (69.8)
Housing settlement
Informal settlement 27 (23.3) 89 (76.7) 0.438
Formal settlement 51 (26.7) 140 (73.3)
Not sure 0 (0) 5 (100)
Daily income for expenditure
Less than 1$ 44 (32.6) 91 (67.4) 0.004
Between 1$-5$ 30 (22.9) 101 (77.1)
>5$ 4 (8.7) 42 (91.3)
Treatment arm
Placebo 45 (31.7) 97 (68.3) 0.013
Acyclovir 33 (19.4) 137 (80.6)
Table 3 Predictors of HIV disease progression at multivariate analysis
Variable Crude Odds
Ratio (cOR)
95 % CI P value Adjusted Odds
Ratio (aOR)
95 % CI p value
Gender
Female 0.6 0.3, 1.0 0.058 0.7 0.3, 1.5 0.354
Male Ref Ref
Age in years 1.01 0.98, 1.04 0.600 0.99 0.95, 1.03 0.497
Expenditure/day
< US$1 5.1 1.7, 15.1 0.003 4.5 1.4, 14.1 0.010
US$ 1-5 3.1 1.0, 9.4 0 .043 3.1 1.0, 9.7 0.057
>US$ 5 Ref Ref
Treatment group
Acyclovir 0.5 0.3, 0.9 0.013 0.6 0.3, 1.0 0.052
Placebo Ref Ref
CD4 at baseline/enrolment CD4
(cube root transformation)
0.3 0.2, 0.4 <0.0 0.3 0.2, 0.4 <0.001
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may benefit from prioritization during implementation of
WHO guidelines.
Conclusions
The association reported between daily income available
for daily expenditure and HIV disease progression indi-
cates that economic empowerment should be considered
as a possible contributor to better health outcomes in
HIV infected individuals. We recommend prioritization of
populations with the lowest daily available incomes for
expenditure in low and middle income countries during
the implementation of HAART scale up.
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